INDIA at TCT 2025: TUXEDO-2 Trial
The TUXEDO-2 trial, led by Dr. Upendra Kaul, compares next-generation drug-eluting stents in diabetic patients.
In patients with diabetes and multivessel coronary artery disease (MVD), the ultra-thin biodegradable polymer sirolimus-eluting stent (Supraflex Cruz, SMT) demonstrated comparable procedural success and safety outcomes to the durable polymer everolimus-eluting stent (Xience, Abbott) when used alongside optimal medical therapy.
The TUXEDO-2 trial is the largest randomized trial to date comparing new-generation drug-eluting stents (DES) in an exclusively diabetic, high-risk population with extensive multivessel coronary disease.
The TUXEDO-2 (Ultra-Thin strUt versus XiencE in a Diabetic pOpulation with Multi-vessel Disease–2) India study
Author's summary: TUXEDO-2 trial compares stents in diabetic patients.
More News
- As AI reshapes shopping, US retailers try to change how they're seen online
- Driven – New Zealand’s Leading Source for Car News, Reviews, and Buyer Insights
- 'Absolutely tremendous' - Zhao Xintong delivers brilliant long red against Long Zehuang at UK Championship
- UK Snooker Championship 2025 LIVE: Zhao Xintong vs Long Zehuang - scores, stream & results
- "There was only 1 game on all of Steam with more reviews than us at 100%," roguelike dev says, and now 54 clown emojis adorn the troll who broke the streak
- Hear and Obey: Living by the Word and Finding True Freedom
- Basic-Fit Shares Climb 4% at Close, Driven by Upward Momentum
- Mercedes driven in zigzag manner, dragged victims: What FIR in Delhi car crash reveals
- World Champion Zhao Xintong Advances Smoothly to UK Championship Last 16
- Radiohead Postpone European Tour After Thom Yorke’s Severe Throat Infection